Hepatitis C Drug Market Share Expected to Reach USD 33.50 Billion by 2022: Zion Market Research

Sarasota, FL, Nov. 29, 2017 -- Zion Market Research has published a new report titled “Hepatitis C Drug Market for Hospitals, Private labs, Physician offices, Public health labs and Blood banks - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022”.  According to the report, the global hepatitis C drug market share accounted for around USD 13.50 billion in 2016 and is expected to reach approximately USD 33.50 by 2022, growing at a CAGR of around 16.0% between 2017 and 2022. 

Hepatitis C virus is a small (55 to 65 nm), spherical, enveloped, hepatotropic RNA virus that causes acute and chronic hepatitis in humans. Persistent virus infection with HCV often leads to cirrhosis and hepatocellular carcinoma (HCC). The WHO estimates that a minimum of 3 percent of the world’s population is chronically infected with HCV. HCV is most commonly spread by direct contact with infected blood and blood products. Availability of injectable therapies and drugs has had a remarkable influence on HCV epidemiology. The incubation period of HCV, though ranging up to several months, averages 6-8 weeks.

Browse through 13 Tables & 27 Figures spread over 110 Pages and in-depth TOC on "Hepatitis C Drug Market for Hospitals, Private labs, Physician Offices, Public Health Labs and Blood Banks - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022”.

Request Free Sample copy of Global Hepatitis C Drug Market Share Analysis Report @ https://www.zionmarketresearch.com/sample/hepatitis-c-drug-market

The global hepatitis C drug market was expected to witness growth over the forecast period due to increase in the prevalence of HCV across the globe. Moreover, lack of awareness is considered as a major governing factor which promotes the demand for hepatitis C drug market. Furthermore, many lifestyle-related factors, such as having multiple sex partners, unsafe sex and transferring of body fluid, are estimated to drive the hepatitis C drug market.  However, lack of awareness and information about HCV, treatment cost, and threat-related to regulation and development of drug may hamper hepatitis C drug market. Nonetheless, new efficient therapies are expected to like to bring growth avenues in hepatitis C market nearby future.

On the basis of end-users, hepatitis C drug market is segmented into five types: hospitals, private labs, physician offices, public health labs and blood banks. These segments are the key end-users of hepatitis C drug market. In terms of revenue, hospitals were the leading end-user in 2016 and the same is expected to be the largest and fastest growing segment during the forecast period. This growth is attributed due to rising number of hospitals and growing hospital investments across the globe. In addition, growing number of patient is also a key driving factor for the growth of hepatitis C drug market.

Browse the full "Hepatitis C Drug Market for Hospitals, Private labs, Physician Offices, Public Health Labs and Blood Banks - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022” report at https://www.zionmarketresearch.com/report/hepatitis-c-drug-market

In terms of geography, North America was the leading market for hepatitis C drug market in 2016 in terms of revenue due to the wide availability of hospitals. Furthermore, lifestyle-related factors such as having multiple sex partners, unprotected sex has become very common in North America and European countries. Moreover, hepatitis C drug has a huge opportunity in emerging market like Asia Pacific and Latin America due to the increasing number of HCV patient, government initiatives, and healthcare infrastructure.

Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/hepatitis-c-drug-market

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global hepatitis C drug market including Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.

For media inquiry contact our sales team @ [email protected]

This report segments the global Hepatitis C drug market as follows:

Global Hepatitis C Drug Market:  End-User Analysis

• Hospitals
• Private labs
• Physician offices
• Public health labs
• Blood Bank

Global Hepatitis C Drug Market: Regional Segment Analysis

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

Related Reports:

• Ingestible Smart Pills Market: https://www.zionmarketresearch.com/report/ingestible-smart-pills-market
• Antifungal Drug Market: https://www.zionmarketresearch.com/report/antifungal-drug-market
• Osteoporosis Drugs Market: https://www.zionmarketresearch.com/report/osteoporosis-drugs-market
• Generic Drug Market: https://www.zionmarketresearch.com/report/generic-drug-market
• Active Pharmaceutical Ingredients market: https://www.zionmarketresearch.com/report/active-pharmaceutical-ingredients-market  

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research

Follow Us Twitter: https://twitter.com/zion_research

Contact Us:

Joel John

4283, Express Lane, Suite 634-143,
Sarasota, Florida 34249, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: [email protected]
Website: https://www.zionmarketresearch.com